Other languages Rallybio Corporation

Equities

RLYB

US75120L1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
1.58 ^USD	+1.28%		-0.63%	-33.89%

May. 15	JPMorgan Downgrades Rallybio to Neutral From Overweight	MT
May. 09	Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting	Apr. 17
Top Premarket Decliners	Apr. 12
US Equity Markets Close Mixed After March Producer Price Inflation Data	Apr. 11
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 11
Aktien New York: Dow erholt sich vor Start in die Berichtssaison	Apr. 11
Top Midday Gainers	Apr. 11
Aktien New York: Dow schwächer vor Start in die Berichtssaison	Apr. 11
Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet	Apr. 11
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report	Apr. 11
Top Premarket Gainers	Apr. 11
Rallybio Corporation Announces Collaboration with Johnson & Johnson	Apr. 10
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12
Rallybio Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12
Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs	Feb. 06
Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116	Dec. 20
Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212	Nov. 28
Rallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting	Nov. 02
Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5	23-09-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rallybio Corporation

Equities

RLYB

US75120L1008

Other languages

Filters